Explore

Rapid Read Rapid Read
FDA Approves Freenome's SimpleScreen CRC Blood-Based Test for Colorectal Cancer Screening

FDA Approves Freenome's SimpleScreen CRC Blood-Based Test for Colorectal Cancer Screening

The U.S. Food and Drug Administration (FDA) has approved Freenome's SimpleScreen CRC, a blood-based screening test for colorectal cancer (CRC) in adults aged 45 and older who are at average risk. This test, which will be commercialized by Abbott in the U.S., offers a new option for CRC screening that requires only a simple blood draw. The approval follows extensive clinical research and collaboration, including the PREEMPT CRC study, which enrolled over 48,000 participants. SimpleScreen CRC demonstrated 81.1% sensitivity in detecting colorectal cancer and 90.4% specificity for advanced colorectal neoplasia. The test aims to increase screening rates among the estimated 60 million Americans overdue for CRC screening.
Rapid Read Rapid Read
European Regulator Approves Eye Implant to Restore Vision in Age-Related Blindness

European Regulator Approves Eye Implant to Restore Vision in Age-Related Blindness

A retinal implant, known as the PRIMA implant, has been approved for use by a European regulator, marking a significant advancement in the treatment of geographic atrophy, a severe form of vision loss associated with age-related macular degeneration. Developed by Science Corporation in Alameda, California, the implant is designed to restore functional central vision, allowing individuals to read and recognize faces. The device, about the size of a pinhead, is inserted beneath the retina and works in conjunction with high-tech glasses equipped with a frame-mounted camera. This system captures images and projects them onto the implant using near-infrared light, which is then converted into electrical pulses to stimulate neurons in the retina. The PRIMA implant has shown promising results, improving visual acuity in about 80% of cases in a small study. It has received Breakthrough Device and Humanitarian Use Device designations from the FDA, paving the way for potential approval in the United States.
Trendline Trendline
Aurenar Secures $5.7M for Neuromodulation Platform Development

Aurenar Secures $5.7M for Neuromodulation Platform Development

Aurenar Secures $5.7M for Neuromodulation Platform Development
Rapid Read Rapid Read
FDA Approves Freenome's Blood-Based Colorectal Cancer Screening Test for U.S. Market

FDA Approves Freenome's Blood-Based Colorectal Cancer Screening Test for U.S. Market

The U.S. Food and Drug Administration (FDA) has approved Freenome's SimpleScreen CRC, a blood-based screening test for colorectal cancer. This test, which will be commercialized by Abbott in the U.S., offers a new option for adults aged 45 and older who are at average risk for colorectal cancer. The approval follows the PREEMPT CRC study, the largest clinical validation study for a blood-based colorectal cancer screening test, involving over 48,000 participants. SimpleScreen CRC detects cancer signals from cell-free DNA in the blood, providing a non-invasive alternative to traditional colonoscopy.
Trendline Trendline
Dasher Neuroscience Completes Enrollment for AI-Driven MSA Drug Trial, Paving Way for New Treatment Options

Dasher Neuroscience Completes Enrollment for AI-Driven MSA Drug Trial, Paving Way for New Treatment Options

Dasher Neuroscience Completes Enrollment for AI-Driven MSA Drug Trial, Paving Way for New Treatment Options
Rapid Read Rapid Read
Nationwide Recall Issued for Levothyroxine Sodium Tablets Due to Subpotency

Nationwide Recall Issued for Levothyroxine Sodium Tablets Due to Subpotency

Major Rugby, a pharmaceutical manufacturer, has issued a nationwide recall for several batches of levothyroxine sodium tablets, a common medication used to treat hypothyroidism and other thyroid-related conditions. The recall affects 12 packages of the medication, which were found to be subpotent, meaning they deliver less medication than intended. Despite the recall, Major Rugby has stated that taking the affected tablets is not likely to cause adverse health effects. The recall includes various dosages and lot numbers, and consumers are advised to return the medication to the point of purchase and consult their healthcare providers if they have the recalled product.
Rapid Read Rapid Read
LifeBridge Health Implements AI Tool for Enhanced Sepsis Detection

LifeBridge Health Implements AI Tool for Enhanced Sepsis Detection

LifeBridge Health's Sinai Hospital in Baltimore has introduced an AI-powered diagnostic tool, Sepsis ImmunoScore, developed by Prenosis, to improve the detection of sepsis. This tool, which received FDA authorization in 2024, analyzes 22 parameters to identify early signs of sepsis, potentially reducing the time to diagnosis to within 24 hours. The tool's implementation follows a collaborative research effort involving multiple centers, including Sinai Hospital, which contributed to the dataset used to train the AI. Sepsis, a challenging and costly condition to manage, affects millions annually in the U.S., with significant mortality rates. The AI tool aims to address diagnostic uncertainties and improve patient outcomes by integrating with hospital electronic medical records.
Rapid Read Rapid Read
FDA Retracts Cyclospora Test on Recalled Lettuce Amid Consumer Reports Criticism

FDA Retracts Cyclospora Test on Recalled Lettuce Amid Consumer Reports Criticism

The FDA has retracted its positive Cyclospora test on recalled lettuce, initially linked to a significant U.S. outbreak. The retraction follows a re-evaluation that deemed the test a false positive. Despite this, the recall remains in place due to epidemiological evidence connecting the lettuce to the outbreak. Consumer Reports criticized the recall notice for using internal abbreviations instead of full brand names, making it difficult for consumers to identify affected products. The recall involves products from Taylor Farms, including those sold under Walmart's Marketside brand. The outbreak has resulted in nearly 2,000 confirmed cases across nine states, with the CDC investigating additional cases.
Rapid Read Rapid Read
Micron Biomedical Secures $4.5 Million Contract for Radiation Medical Countermeasure

Micron Biomedical Secures $4.5 Million Contract for Radiation Medical Countermeasure

Micron Biomedical, a clinical-stage life science company, has been awarded a $4.5 million contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH). The contract is aimed at developing the world's first dissolvable microarray medical countermeasure against radiation injury. This innovative approach is designed to improve national preparedness against nuclear threats by enabling rapid deployment of treatments for Acute Radiation Syndrome (ARS). The technology involves a thermostable, needle-free delivery system that can be administered by minimally trained personnel or self-administered, thus facilitating quick response in emergency scenarios.
Rapid Read Rapid Read
FDA Clears AI Tool EchoNext for Early Detection of Heart Failure via ECG

FDA Clears AI Tool EchoNext for Early Detection of Heart Failure via ECG

The U.S. Food and Drug Administration has cleared EchoNext, an AI tool developed by Pathway Labs in collaboration with NewYork-Presbyterian and Columbia University Irving Medical Center, to detect structural heart disease from routine ECGs. This tool can identify six cardiac conditions, including heart failure and valve disease, which are often asymptomatic in early stages. EchoNext was trained on a large dataset of ECGs and echocardiograms and validated across multiple hospitals. It aims to bridge the gap between routine ECGs and more costly echocardiograms, offering a new layer of screening that could lead to earlier diagnosis and treatment.
Rapid Read Rapid Read
Miami Cancer Institute's Clinical Trial Offers Hope for Late-Stage Pancreatic Cancer Patients

Miami Cancer Institute's Clinical Trial Offers Hope for Late-Stage Pancreatic Cancer Patients

Hernando Salcedo, an 83-year-old grandfather, was diagnosed with Stage III pancreatic cancer in May 2025. After experiencing severe side effects from traditional chemotherapy, Salcedo was presented as a candidate for a clinical trial at the Miami Cancer Institute. The trial involved a new chemotherapy delivery device from RenovoRX, designed to target the tumor more precisely and reduce side effects. The RenovoCath system uses a catheter to deliver chemotherapy directly to the tumor, minimizing exposure to the rest of the body. This method has shown to reduce adverse effects and increase survival rates. Salcedo participated in the trial and reported significant improvements in his quality of life, experiencing fewer side effects compared to traditional chemotherapy.
Rapid Read Rapid Read
Retatrutide Emerges as a Potential Successor to Semaglutide in Obesity Treatment

Retatrutide Emerges as a Potential Successor to Semaglutide in Obesity Treatment

Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, is gaining attention as a potential successor to semaglutide for obesity treatment. Unlike semaglutide, which targets only the GLP-1 receptor, retatrutide's broader mechanism may offer enhanced metabolic effects and greater weight loss. Phase 2 clinical trials have shown promising results, with participants losing up to 24% of body weight over 48 weeks. However, retatrutide is still investigational and lacks FDA approval. Patients transitioning from semaglutide to retatrutide are advised to start at a low dose and follow a structured titration schedule to minimize side effects.